Health News-RSS Feeds
Exclusive: Lilly expects US Medicare to reverse course, fully cover Alzheimer’s drugs
Reuters exclusively reported that Eli Lilly and Co expects the U.S. Medicare health plan to lift strict coverage limits on new Alzheimer’s drugs as data emerges on the treatment’s ability to clear amyloid brain plaques and help patients. Derek Asay, Lilly’s SVP of Government Strategy and Federal Accounts, told Reuters that the agency will soon have the evidence it needs to provide robust reimbursement for amyloid-reducing drugs like the company’s experimental donanemab. The agency’s current plan would only require it to pay for the drug once it receives US Food and Drug Administration approval if patients are part of a registry, a move Lilly said would create inequity in its use. Lilly has not previously discussed publicly its optimism about a change at Medicare, which covers 85% of the Americans who have the mind-wasting disease. The news lifted shares of Lilly by $11.13, or 3%, to $385.96 on Friday.
The post Exclusive: Lilly expects US Medicare to reverse course, fully cover Alzheimer’s drugs appeared first on Reuters News Agency.
Syneos Health eyes sale of company as contract backlog shrinks
Shares of Syneos Health Inc rose 13% after Reuters exclusively reported that the company is making a new effort to sell itself. The effort comes in the wake of a reduced backlog of contracts for providing clinical research to drug developers that led to a plunge in the value of its shares over the past year. Syneos has hired Bank of America Corp and Centerview Partners LLC for financial advice as it embarks on a new round of talks with potential acquirers that may include industry peers and private equity firms.
The post <strong>Syneos Health eyes sale of company as contract backlog shrinks</strong> appeared first on Reuters News Agency.